Loading, please wait...
Due to concerns about the novel coronavirus, and consistent with ongoing efforts to reduce spread of the virus, attendance for the November CE sessions will be WEBINAR ONLY. Please see instructions below for registration.
PLEASE FOLLOW THE STEP-BY-STEP INSTRUCTIONS BELOW – DO NOT SKIP STEPS!
STEP 1: SIGN INTO YOUR ACCOUNT AND REGISTER FOR EACH SESSION YOU WOULD LIKE TO ATTEND
** If you do not register for the CE at this link, you will not be able to access the evaluations to earn credit
** EVERYONE must register BEFORE the session date. NO NEW REGISTRATIONS WILL BE ADDED AFTER THE PROGRAM DATE
** You will receive an email confirming your registration at the email address provided – if you do not receive a confirmation email, try to register again
**New sessions may be added throughout the month, so do not assume you are registered for all sessions.
STEP 2: AFTER SUCCESSFULLY REGISTERING - AT THE TIME OF THE PROGRAM, EXPAND THE MODULE AND CLICK THE WEBEX LINK
** submit your contact information
STEP 3: Collect the presenter code for each of the CEs that you attend
** EVERYONE will need the presenter codes to access evaluations and earn CE credit
STEP 4: You will receive an automated email to log in and complete evaluations
** Evaluations must be completed within 60 days of the CE session
** You will need the presenter codes to access each evaluation
** Evaluations MUST be completed within 60 days of the program date to earn CE credit!
Date: Dec 1, 2020 01:00 AM - Dec 20, 2020 11:55 PM
CE Hours
3.00
CE Units
0.300
Registration closes on Dec 20, 2020 01:00 AM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
Participants have 60 days from the start of their program to claim CE credit and verify it has been upload to CPE Monitor. If your program requires the completion of a post test/eval/survey those items MUST be done before that 60 day window closes to receive credit for that program. Statements of credit can be viewed and printed from CPE Monitor. Statements of credit will no longer be printed and mailed to the participant. **No partial individual session credit will be given**
REGISTRATION NOTE: During the registration process, if a fee is required, please enter the zip code associated with your credit card's BILLING ADDRESS. For security purposes payments are processed through a separate system, so when prompted, please click “ok” to be taken to that site and complete your registration. Upon successful registration of this program you will receive an email confirmation/receipt and will be returned to this program page. When you are retuned to this page you will see a note at the top of the page reading “You are registered for this program.”
If you are not automatically returned to this page or see only a blank white screen your transaction was not successful, and you will need to try again.
If paying by check please mail to the address below: 301 Pharmacy Lane, CB# 7574 Beard Hall
Chapel Hill, NC 27599
|
|
|
The University of North Carolina Eshelman School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To receive CE credit, participants must complete the CE attendance form and the online evaluation of the program (instructions to be emailed). Statements of credit can be viewed and printed in CPE Monitor approximately 2 to 3 weeks after the program and you have completed any needed requirements. **No partial credit will be available**
|
Co-Sponsor(s)
UNC Health System
Support/Credits
Cancelations: Cancelations must be received in writing/email to the Office of Continuing Education at least 48 hours prior to start date to receive a full refund. No refunds will be given within 48 hours of the start date.
IMPORTANT: UNC HEALTH SYSTEM EMPLOYEES AND UNC ESHELMAN SCHOOL OF PHARMACY STUDENTS ONLY
UNC Health System Employees and ESOP Students are able to attend this Resident Series at no charge to them. If you are a Health System Employee or Student please follow the steps below. This only applies to this series.
- UNC Health System Employees and UNC ESOP Students should register using your UNC email address. UNC Employees - please select your employment location during the registration process. UNC Students - please respond "Yes" to the "Are you a UNC Student" question.
- Select the “Check” payment method on the registration page. Your employment will be verified prior to credit being uploaded
Registration closes on Dec 20, 2020
at 01:00 AM
Registration closes on Dec 20, 2020
at 01:00 AM
Registration Closed
Registration Closed
This presentation is intended to review current guideline-recommended pharmacological and non-pharmacological options for the management of acute ischemic stroke (AIS) and critically evaluate literature examining the outcomes, both positive and negative, of alteplase use in AIS.
Meeting: 160 483 1545
Password: UNCPharm1
Presentation Slides available for download at the bottom of this module. You MUST be signed into your registered account to access this content
Objectives
- Describe the pathophysiology, clinical manifestations, and diagnosis of acute ischemic stroke (AIS)
- Outline the literature examining outcomes for administering alteplase in AIS
- Discuss evidence-based recommendations regarding the appropriate use of alteplase in AIS
- Apply appropriate use of alteplase in AIS to a patient case
Speaker(s)/Author(s)
|
Sarah Elizabeth Davis, PharmD
|
Activity Number
0046-9999-20-376-L01-P
Date:
12/03/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Location
Online
Registration Closed
Registration closes on Dec 20, 2020
at 01:00 AM
Registration closes on Dec 20, 2020
at 01:00 AM
Registration Closed
Registration Closed
The use of aspirin at a dose of 81 -325 mg daily in patients with a durable, continuous flow LVAD had been a Class I, LOE C recommendation in the 2010 and 2013 versions of the ISHLT LVAD guidelines/consensus reviews despite no prospective, controlled data to allow for a precise assessment of its role in the prevention of, or contribution to, hemocompatability related adverse events. Since then, several retrospective reviews of aspirin use in clinical practice have led to adjustments in recommendations based on device type. This presentations aims to present information to help guide the future use of antiplatelets in patients with durable continuous flow LVADs.
Meeting ID: 160 925 2086
Password: UNCPharm1
Presentation Slides available for download at the bottom of this module. You MUST be signed into your registered account to access this content
Objectives
- Outline the pathophysiology, assessment, and consequence of platelet dysfunction with LVADs
- Discuss the historical use of anti-platelet agents in patients with left ventricular assist devices (LVADs)
- Analyze the evidence behind current anti-thrombotic practices in patients with an LVAD
- Discuss the risks and benefits of anti-platelet therapy in addition to anticoagulation in patients with an LVAD
Speaker(s)/Author(s)
|
Ryan Vesper, PharmD
|
Activity Number
0046-9999-20-341-L01-P
Date:
12/10/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Location
Online
Registration Closed
Registration closes on Dec 20, 2020
at 01:00 AM
Registration closes on Dec 20, 2020
at 01:00 AM
Registration Closed
Registration Closed
Following this session, pharmacists will learn the background of mycobacterium abscessus associated pulmonary disease along with the backbone of therapy. Additionally pharmacists will become more knowledgeable of clofazimine and how it can be used to manage refractory mycobacterium abscessus in pediatric, cystic fibrosis patients. However, while learning this information, pharmacists should become more aware of the risks and adverse effects that accompany clofazimine. This sessions will utilize a patient case to highlight key details.
Meeting: 160 295 0905
Password: UNCPharm1
Presentation Slides available for download at the bottom of this module. You MUST be signed into your registered account to access this content
Objectives
- Discuss Mycobacterium abscessus-associated pulmonary disease in pediatric cystic fibrosis patients
- Identify guideline based therapy recommended to treat Mycobacterium abscessus pulmonary disease
- Discuss the pharmacology and clinical concerns associated with the use of clofazimine
- Outline a plan for treatment of refractory Mycobacterium abscessus pulmonary disease including clofazimine
Speaker(s)/Author(s)
|
Matt Whiteman, PharmD
|
Activity Number
0046-9999-20-380-L01-P
Date:
12/17/20
Time:
05:00 PM - 06:00 PM
CE Hours
1.00
Location
Online
Registration Closed